Recent News

• 06.26.2026 - Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series
• 06.25.2026 - Phio Pharmaceuticals Announces “How siRNA Therapy can Change the Course of Cancer Treatment” in a Fireside Chat with Force Family Office on Monday, June 29, 2026
• 06.24.2026 - Phio Pharmaceuticals Reaches Key Milestone in Advancing Lead Candidate PH-762
• 06.18.2026 - Phio Pharmaceuticals Announces Participation in the Life Sciences Investor Forum on June 24-25, 2026
• 05.26.2026 - Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series
• 05.12.2026 - Phio Pharmaceuticals Announces “Innovations in Skin Cancer Treatment and Prevention” in a Fireside Chat with Force Family Office on Tuesday, May 19, 2026
• 05.07.2026 - Phio Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Update
• 04.23.2026 - Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series
• 04.13.2026 - Phio Pharmaceuticals Announces “Nobel Prize Winning Science Takes on Skin Cancer” in a Fireside Chat with Force Family Office on Wednesday, April 15, 2026
• 04.09.2026 - Phio Pharmaceuticals Announces Presentation at Centri Capital Conference on April 14, 2026

Recent Filings

• 06.29.2026 - 4 Statement of changes in beneficial ownership of securities
• 05.07.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 05.07.2026 - 8-K Current report
• 05.07.2026 - EX-99.1 EX-99.1
• 04.08.2026 - 8-K Current report
• 04.08.2026 - 424B5 Prospectus [Rule 424(b)(5)]
• 03.30.2026 - 8-K Current report
• 03.05.2026 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 03.05.2026 - 8-K Current report
• 03.05.2026 - EX-99.1 EX-99.1